INVESTOR ALERT: 

This is Your Ticket to the Nanotech Revolution:

(Ticker Revealed Below)

Fellow investor, 

A new nanotechnology could quickly become a potentially winning investing trend for 2024.

One small company is developing a potentially breakthrough anti-bacterial technology inspired by the “sacred” lotus plant…

But this technology doesn’t just repel water…

Its nanoscopic wrinkles are at least a BILLION times smaller than we can see with the naked eye.

And in lab results, it’s been able to fend off bacteria and viruses too.

In fact, Science Daily reports that its surface “repels even the deadliest superbugs.”

Even more exciting…

Market research firm, Future Markets, estimates the antimicrobial coating market could TRIPLE IN SIZE to $11 billion in the next 5 years.

Meaning, this patent-pending technology may provide a significant opportunity for this small company future products.

Which is why we think this opportunity should be added to your radar.

Here’s how this play could explode in the coming months…

ABOUT INVESTING INSIDER

Investing Insider is a financial education and publishing company. Our team of editors deliver daily tips, picks, and stock market analysis.  Whether you prefer low-risk, deep-value strategies… income investing… or high-risk, high-reward speculative stock picks, we can offer actionable investing ideas to help grow your wealth.
Copyright © 2023 Investing Insider Publishing Ltd. All rights reserved.
30 N Gould St, Suite 2737, Sheridan, WY 82801

Simply input your email below to reveal the company and ticker:

(By inputting your email below you agree to receive emails from Investing Insider. You can opt out at anytime.)  

By requesting an investor information package, you agree to our Privacy Policy & Terms

1 – https://finance.yahoo.com/quote/MSFT/history?p=MSFT (opening price of $243.08 on Jan3, 2023 to closing price of $430.30 on September 30, 2024)

2 – https://finance.yahoo.com/quote/META/history?p=META (opening prices of $122.82 on Jan3,2023 to cloasing price of $572.44 on Sep 30, 2024)

3 – https://finance.yahoo.com/quote/NVDA/history?p=NVDA (opening price of $14.31 on Jan3,2023 to closing price of $121.44 on Sep 30, 2024)

4 – https://www.weforum.org/agenda/2023/01/global-growth-story-of-the-21st-century-lse-grantham-systemiq-davos2023/

5 – https://www.globalbankingandfinance.com/artificial-intelligence-the-future-of-investment/

6 – https://www.pwc.co.uk/services/human-resource-services/insights/is-workforce-ready-for-ai.html

7 – https://sitn.hms.harvard.edu/flash/2020/modern-drug-discovery-why-is-the-drug-development-pipeline-full-of-expensive-failures/

8 – https://www.eidasolutions.com/the-pharmaceutical-industry-in-figures/

9 – https://vakilsearch.com/blog/what-is-the-most-profitable-pharmaceutical-drug-ever/

10 – https://www.drugdiscoverytrends.com/top-pharma-rd-spenders-2022/

11 – https://www.fiercebiotech.com/biotech/top-10-pharma-rd-budgets-2022

12 – https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html

13 – https://www.pharmaceutical-technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/

14 – https://www.fiercebiotech.com/special-reports/2022s-top-10-clinical-trial-flops

15 – https://www.biospace.com/article/phase-iii-flop-ends-sanofi-s-breast-cancer-serd-candidate/

16 – https://www.fiercebiotech.com/biotech/merck-co-bails-ngm-eye-disease-collab-wake-phase-2-fail

17 – https://finance.yahoo.com/news/pfizer-cuts-stage-asset-rare-174713321.html

18 – https://ftloscience.com/process-costs-drug-development/

19 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/

20 -https://ftloscience.com/process-costs-drug-development/

21 – NetraMark Deck 2023, slide 11

22 – https://www.pfizer.com/science/clinical-trials/guide-to-clinical-trials/meet-people

23 – https://www.koreabiomed.com/news/articleView.html?idxno=21181

24 – https://www.prnewswire.com/news-releases/sanofi-accelerating-future-breakthroughs-through-clinical-trials—part-1-of-3-300647127.html

25 – https://www.statista.com/statistics/732997/number-of-registered-clinical-studies-worldwide/

26 – https://www.fiercebiotech.com/biotech/top-10-pharma-rd-budgets-2022

27 – https://www.weforum.org/agenda/2023/01/global-growth-story-of-the-21st-century-lse-grantham-systemiq-davos2023/

28 – https://eandt.theiet.org/content/articles/2023/01/money-markets-ai-is-the-investors-next-big-thing/

29 – https://www.forbes.com/sites/bernardmarr/2022/10/19/the-disruptive-economic-impact-of-artificial-intelligence/?sh=6257b0f940b7

30 – https://www.bbc.co.uk/news/business-65675027

31 – $148.51 open on January 3, 2023 to $424.13 close July 3, 2023.

32 – https://synthedia.substack.com/p/stability-ai-is-raising-funds-at

33 – https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/

34 – https://www.pharmaceutical-technology.com/features/featurecounting-the-cost-of-failure-in-drug-development-5813046/

Simply input your email below to reveal the company and ticker:

(By inputting your email below you agree to receive emails from Investing Insider. You can opt out at anytime.)  

By requesting an investor information package, you agree to our Privacy Policy & Terms